Bansal Keshav, Chaudhary Neeraj, Bhati Hemant, Singh Vanshita
Institute of Pharmaceutical Research, GLA University, Mathura-281406, Uttar Pradesh, India.
Curr Pharm Biotechnol. 2025;26(1):48-62. doi: 10.2174/0113892010314650240514053735.
Urological cancers are one of the most prevalent malignancies around the globe. Specifically, bladder cancer severely threatens the health of humans because of its heterogeneous and aggressive nature. Extensive studies have been conducted for many years in order to address the limitations associated with the treatment of solid tumors with selective substances. This article aims to provide a summary of the therapeutic drugs that have received FDA approval or are presently in the testing phase for use in the prevention or treatment of bladder cancer. In this review, FDA-approved drugs for bladder cancer treatment have been listed along with their dose protocols, current status, pharmacokinetics, action mechanisms, and marketed products. The article also emphasizes the novel preparations of these drugs that are presently under clinical trials or are in the approval stage. Thus, this review will serve as a single point of reference for scientists involved in the formulation development of these drugs.
泌尿系统癌症是全球最常见的恶性肿瘤之一。具体而言，膀胱癌因其异质性和侵袭性严重威胁人类健康。多年来已开展了广泛研究，以解决与使用选择性物质治疗实体瘤相关的局限性。本文旨在总结已获得美国食品药品监督管理局（FDA）批准或目前正处于测试阶段用于预防或治疗膀胱癌的治疗药物。在本综述中，列出了FDA批准的用于膀胱癌治疗的药物及其剂量方案、当前状态、药代动力学、作用机制和上市产品。本文还强调了这些药物目前正在进行临床试验或处于批准阶段的新制剂。因此，本综述将为参与这些药物制剂开发的科学家提供一个单一的参考点。
